Published in J Clin Immunol on March 01, 1987
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Clinical practice: Herpes zoster. N Engl J Med (2013) 5.16
Varicella-zoster virus. Clin Microbiol Rev (1996) 3.03
Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis (2008) 1.70
Quantitation of varicella-zoster virus DNA in patients with Ramsay Hunt syndrome and zoster sine herpete. J Clin Microbiol (2001) 1.45
Shingles Immunity and Health Functioning in the Elderly: Tai Chi Chih as a Behavioral Treatment. Evid Based Complement Alternat Med (2004) 1.18
Virus vasculopathy and stroke: an under-recognized cause and treatment target. Infect Disord Drug Targets (2010) 1.11
Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. J Virol (1992) 1.04
Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol (1994) 1.01
Old mice express a transient early resistance to pulmonary tuberculosis that is mediated by CD8 T cells. Infect Immun (2002) 1.01
Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study. Ophthalmology (2012) 0.88
Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs. J Virol (1991) 0.86
The Characterization of Varicella Zoster Virus-Specific T Cells in Skin and Blood during Aging. J Invest Dermatol (2015) 0.85
T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol (1990) 0.82
Inhibition of varicella-zoster virus in vitro by human peripheral blood mononuclear cells. Clin Exp Immunol (1989) 0.82
Epidemiology of Herpes Zoster Ophthalmicus: Recurrence and Chronicity. Ophthalmology (2016) 0.78
Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infect Dis (2016) 0.77
Immunological correlates of vaccination and infection for equine herpesvirus 1. Clin Vaccine Immunol (2011) 0.76
Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis (2016) 0.75
Initial Presentation Sites as Predictors of Herpes Zoster Complications: A Nationwide Cohort Study. PLoS One (2016) 0.75
Prevention of shingles: safety and efficacy of live zoster vaccine. Ther Clin Risk Manag (2007) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
IgA deficiency, epilepsy, and phenytoin treatment. Lancet (1975) 2.40
Fc-receptor heterogeneity of human suppressor T cells. J Immunol (1978) 2.37
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
Inhibition of complement-dependent lymphocyte rosette formation: a possible test for activated complement products. Eur J Immunol (1974) 2.12
Induction of plasma cell differentiation of human fetal lymphocytes: evidence for functional immaturity of T and B cells. J Immunol (1977) 1.94
Delayed separation of the umbilical cord, widespread infections, and defective neutrophil mobility. Lancet (1979) 1.50
The inhibition of complement-dependent lymphocyte rosette formation by the sera of children with steroid-sensitive hephrotic syndrome and other renal diseases. Clin Exp Immunol (1975) 1.49
Varicella-zoster virus infection of human mononuclear cells. Virus Res (1987) 1.46
Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis (1992) 1.45
Primary and secondary abnormalities of T cell subpopulations. Clin Exp Immunol (1978) 1.43
Suppression of B lymphocyte differentiation by newborn T lymphocytes with an Fc receptor for IgM. Clin Exp Immunol (1978) 1.36
Treatment of pneumocystis carinii pneumonia in children. Arch Dis Child (1977) 1.33
Cellular immunity to varicella-zoster virus in patients with major depression. J Infect Dis (1998) 1.27
Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun (1998) 1.27
Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis (1998) 1.20
Pre-B and B cells in children on leukaemia remission maintenance treatment. Clin Exp Immunol (1979) 1.19
Echovirus encephalitis and myositis in primary immunoglobulin deficiency. Arch Dis Child (1978) 1.18
Defect of neutrophil mobility with dominant inheritance in a family with Waardenberg's syndrome. Arch Dis Child (1981) 1.14
Central failure of B-lymphocyte induction in pan-hypogammaglobulinemia. Clin Immunol Immunopathol (1975) 1.14
Helper and suppressor-inducer activity of human T cells and their cloned progeny maintained in long-term culture. J Immunol (1981) 1.12
Characterization of the T lymphocyte colony-forming cells and evidence for the acquisition of T cell markers in the absence of the thymic microenvironment in man. J Immunol (1981) 1.10
Specific lysis of varicella zoster virus-infected B lymphoblasts by human T cells. J Virol (1986) 1.10
Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis (1994) 1.10
Development of lymphocyte responses and interactions in the human fetus and newborn. Immunol Rev (1981) 1.08
Newborn T cell suppression: early appearance, maintenance in culture, and lack of growth factor suppression. J Immunol (1981) 1.07
Development of lymphocyte populations in the human foetal thymus and spleen. Clin Exp Immunol (1974) 1.06
Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. J Virol (1992) 1.04
Degeneration of aortic valve allografts in young recipients. J Thorac Cardiovasc Surg (1993) 1.03
Characterization of the human newborn response to herpesvirus antigen. J Immunol (1985) 1.02
X-linked immunodeficiency with hyper-IgM (XHIM). Clin Exp Immunol (2000) 1.02
Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol (1994) 1.01
T-lymphocyte subpopulations in insulin-dependent (type I) diabetes mellitus. Clin Exp Immunol (1986) 0.98
Use of bone marrow fibroblasts to prepare targets for an HLA restricted-cytotoxicity assay system. J Clin Microbiol (1984) 0.97
Requirement for OKT8+ suppressor cell proliferation for suppression by human newborn T cells. Clin Exp Immunol (1981) 0.95
Induction of suppression through human T cell interactions. Clin Exp Immunol (1980) 0.95
Immune responses to varicella zoster virus infections in healthy children. J Infect Dis (1993) 0.94
Inhibition of herpes simplex virus type 1 replication in fibroblast cultures by human blood mononuclear cells. J Virol (1986) 0.93
T cell growth factor-enhanced PHA response of human thymus cells: requirement for T3+ cells. J Immunol (1981) 0.92
Growth of pre-B cells in cultures of bone marrow from children with acute lymphoblastic leukaemia and other diseases. Clin Exp Immunol (1981) 0.92
Desferoxamine blocks IL 2 receptor expression on human T lymphocytes. J Immunol (1986) 0.91
Existence of a pool of T-lymphocyte colony-forming cells (T-CFC) in human bone marrow and their place in the differentiation of the T-lymphocyte lineage. Blood (1981) 0.90
Culture and phenotype of activated T-cells from patients with type I diabetes mellitus. Diabetes (1984) 0.90
Hypoimmunoglobulinaemia with deficiency of pre-B cells. Lancet (1978) 0.90
Expression of b 4 and b 5 chi light chain allotypes by B and pre-B cells in allotype-suppressed and neutralized b4b5 rabbits. Eur J Immunol (1979) 0.89
Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients. Clin Exp Immunol (1985) 0.89
The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am (1996) 0.88
Pre-B cell suppression by thymoma patient lymphocytes. Clin Exp Immunol (1982) 0.88
Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster virus cell-mediated immunity. J Clin Microbiol (1996) 0.87
Phenotype and function of human milk monocytes as antigen presenting cells. Clin Immunol Immunopathol (1982) 0.87
Pre-B and B cells in rabbits. Ontogeny and allelic exclusion of kappa light chain genes. J Exp Med (1978) 0.86
Immune response to split-product influenza vaccine in preterm and full-term young children. Vaccine (1992) 0.85
Processing and presentation of cell-associated varicella-zoster virus antigens by human monocytes. Clin Exp Immunol (1987) 0.85
IgG subclass of anti-HSV antibodies following neonatal HSV infections. Eur J Pediatr (1986) 0.84
Acyclovir-resistant neonatal herpes simplex virus infection of the larynx. J Pediatr (1994) 0.84
Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine (1994) 0.84
T cell proliferative response to interleukin 2: different frequency of responders among CD45R0 and CD45RA subsets. Cell Immunol (1990) 0.83
Specific immunity after congenital or neonatal infection with cytomegalovirus or herpes simplex virus. J Immunol (1984) 0.83
Impaired neonatal natural killer-cell activity to herpes simplex virus: decreased inhibition of viral replication and altered response to lymphokines. J Clin Immunol (1986) 0.83
Intact intestinal mRNAs and intestinal epithelial cell esterase, but not Cryptosporidium parvum, reach mesenteric lymph nodes of infected mice. J Immunol (2001) 0.82
Identification of cells with monocyte markers in panhypogammaglobulinaemia. Scand J Immunol (1975) 0.82
Inhibition of varicella-zoster virus in vitro by human peripheral blood mononuclear cells. Clin Exp Immunol (1989) 0.82
Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine (2000) 0.82
Cellular interactions in the lysis of varicella-zoster virus infected human fibroblasts. Clin Exp Immunol (1986) 0.81
Neutrophil pyruvate kinase deficiency with recurrent staphylococcal infections: first reported case. Br Med J (1976) 0.81
Double fluorescence technique for measurement of complement-fixing antibody to lymphocyte subsets. J Immunol Methods (1985) 0.81
Herpes simplex virus-stimulated gamma-interferon production by newborn mononuclear cells. Pediatr Res (1986) 0.81
Resistance of pokeweed mitogen-stimulated B cells to inhibition by deoxyadenosine. Clin Exp Immunol (1980) 0.81
Respiratory syncytial virus infects the Bonnet monkey, Macaca radiata. Pediatr Dev Pathol (1999) 0.80
B cell function in the newborn. Pediatrics (1979) 0.80
Probable graft-vs-graft reaction in an infant after exchange transfusion and marrow transplantation. Pediatrics (1982) 0.80
Non-specific induction of cytoxicity by human lymphocytes with human IgG. Immunology (1974) 0.79
Requirement for TNF-Tnfrsf1 signalling for sclerosing cholangitis in mice chronically infected by Cryptosporidium parvum. Clin Exp Immunol (2002) 0.79
The human fetus and newborn: development of the immune response. Birth Defects Orig Artic Ser (1983) 0.78
Failure of a pan-reactive anti-T cell antibody, OKT 3, to prevent graft versus host disease in severe combined immunodeficiency. J Pediatr (1982) 0.78
Differential response of human thymus cells to CD2 antibodies: fragmentation of DNA of CD45RO+ and proliferation of CD45RO- subsets. Immunology (1992) 0.78
Response of human newborn lymphocytes to alloantigen: lack of evidence for suppression induction. Pediatr Res (1984) 0.78
Four families with immunodeficiency and chromosome abnormalities. Arch Dis Child (1979) 0.78
Phenotyping of proliferating cells in cultures of human lymphocytes. J Immunol Methods (1985) 0.77
Noma in children with severe combined immunodeficiency. J Pediatr (1986) 0.77
Chronic fatigue syndrome: I. Epstein-Barr virus immune response and molecular epidemiology. J Med Virol (1991) 0.77
Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus-infected endothelial cells: role of MHC class I antigens. Viral Immunol (2000) 0.77
Development of the immune response. Clin Allergy (1973) 0.77
Reduced cellular immunity to varicella zoster virus during treatment for acute lymphoblastic leukemia of childhood: in vitro studies of possible mechanisms. J Clin Immunol (1986) 0.77
Increase and inhibition of pre-B cell proliferation in culture, by T cells. Clin Exp Immunol (1981) 0.75
Progressive restriction of antigen binding by human foetal thymus lymphocytes. Immunology (1976) 0.75
Immunity to herpes simplex virus in children receiving treatment for acute lymphoblastic leukaemia (ALL). Clin Exp Immunol (1985) 0.75
Human newborn autologous mixed lymphocyte response: frequency and phenotype of responders and xenoantigen specificity. J Immunol (1984) 0.75
Immune response to varicella-zoster virus 5 years after acyclovir therapy of childhood varicella. J Infect Dis (1995) 0.75
Dissociation among Ia antigen expression, accessory cell function, and antigen processing in two acute monoblastic leukemia lines. J Clin Immunol (1984) 0.75
T-lymphocytes: an update. Pediatr Ann (1987) 0.75
Acute renal failure--10-year experience of the Johannesburg Hospital renal unit. S Afr Med J (1987) 0.75
Human tonsillar IgE biosynthesis in vitro. II. Analysis of T cell regulation with monoclonal antibodies. J Allergy Clin Immunol (1988) 0.75
Function of the transplanted thymus. Lancet (1970) 0.75
A cytotoxic monoclonal islet cell surface antibody from the NOD mouse. J Clin Lab Immunol (1989) 0.75